A
Alcista
Alcista · 25%DNA
$11.62
Precio del escenario
$9.710
-0.291 (-3.00%)Al cierre
Loading chart…
- Máximo
- 10.140
- Apertura
- 9.690
- Precio medio ponderado por volumen
- 9.78
- Volumen
- 1.98M
- Capitalización
- 683.73M
- Mínimo
- 9.500
- Importe
- 19.36M
- EV/EBITDA, TTM
- -4.49
Ginkgo Bioworks Holdings, Inc. offers biological research and development (R&D) services on its platform and autonomous laboratory to enable its customers to bring their products to market. The Company sells tools and biological R&D services across a range of industries to government and commercial customers. Its in-house autonomous lab is available as Cloud Lab through its Datapoints and Solutions contract research services. Its single segment, namely cell engineering, provides tools and biological R&D services across a range of industries. Its cell engineering customers work with biology to discover and manufacture new products across industries such as medicine, agriculture, industrial biotechnology and government. It provides R&D services spanning genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. It provides a suite of microservices for product developers across industries that support bioengineers with protein engineering.
Análisis de IA of Ginkgo Bioworks Holdings Inc (DNA)
VenderGinkgo Bioworks is not a good buy right now due to its significant financial struggles and negative market sentiment. The current price is $10.27, and the company reported a staggering 21% decline over the last five days. Additionally, the RSI is at 35.487, indicating oversold conditions but also reflecting weak momentum. The recent downgrade by TD Cowen, coupled with insider selling increasing by 74248.78%, suggests a lack of confidence in the company's near-term growth prospects, making it a risky investment at this time.
Recomendaciones de analistas (2)
+23.58% de potencial alcista
Vender
0 Comprar
0 Mantener
2 Vender
Actual: 9.71
Mínimo
12.00
Promedio
12.00
Máximo
12.00
TD Cowen
Mantener
$9
2026-08-07
TD Cowen
2026-08-07
Precio objetivo
$9
Mantener
BTIG
Vender
$5
2026-03-12
BTIG
2026-03-12
Precio objetivo
$5
Vender
TD Cowen
Comprar
$12
2026-01-08
TD Cowen
2026-01-08
Precio objetivo
$12
Comprar
BTIG
Vender
$9
2025-08-25
BTIG
2025-08-25
Precio objetivo
$9
Vender
TD Cowen
Comprar
$16
2025-08-08
TD Cowen
2025-08-08
Precio objetivo
$16
Comprar
Métricas de valoración
El PER previsto actual de Ginkgo Bioworks Holdings Inc (DNA) es 0.00, frente a su media de 5 años de -6.41.
Escenarios de precio de Alphio AI para DNA
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con DNA en cartera
Cronología de eventos
Noticias
7.510-09PRnewswireGinkgo Integrates Araceli's High-Throughput Imaging Technology
7.510-08NewsfilterGinkgo Bioworks Supports NSF X-Labs Program with Autonomous Lab Access
7.510-08PRnewswireGinkgo Bioworks Integrates Araceli's High-Throughput Imaging Technology
7.510-08PRnewswireAraceli and Ginkgo Enhance Cellular Imaging Capabilities
7.510-08PRnewswireGinkgo Integrates Araceli's Endeavor for Enhanced Cellular Data Generation
Preguntas frecuentes sobre DNA, respondidas por Alphio AI
Ginkgo Bioworks Holdings, Inc. offers biological research and development (R&D) services on its platform and autonomous laboratory to enable its customers to bring their products to market. The Company sells tools and biological R&D services across a range of industries to government and commercial customers. Its in-house autonomous lab is available as Cloud Lab through its Datapoints and Solutions contract research services. Its single segment, namely cell engineering, provides tools and biological R&D services across a range of industries. Its cell engineering customers work with biology to discover and manufacture new products across industries such as medicine, agriculture, industrial biotechnology and government. It provides R&D services spanning genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. It provides a suite of microservices for product developers across industries that support bioengineers with protein engineering. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Ginkgo Bioworks is not a good buy right now due to its significant financial struggles and negative market sentiment. The current price is $10.27, and the company reported a staggering 21% decline over the last five days. Additionally, the RSI is at 35.487, indicating oversold conditions but also reflecting weak momentum. The recent downgrade by TD Cowen, coupled with insider selling increasing by 74248.78%, suggests a lack of confidence in the company's near-term growth prospects, making it a risky investment at this time.
2 analysts cover DNA: 0 rate it Buy, 0 Hold and 2 Sell. The average price target is 12.00.
Comunidad
Más ↗
$RT1 $DOGE 🚨 DNA IS TESTING A MAJOR RESISTANCE...... A BREAKOUT COULD CHANGE THE PICTURE! 📈 $DNA Buyers have stepped back in, and RSI(6) near 55 suggests mildly bullish momentum. However, the recent rejection near $0.22011 shows that sellers are still defending higher prices. 📈 If buyers break above $0.22011 with strong volume, the price could move toward $0.23180. But if resistance holds and momentum fades, DNA may pull back toward $0.19120, with $0.17168 as the key support to watch. 👀 Key levels to watch: 🟢 Support: $0.19120 – $0.17168 🔴 Resistance: $0.22011 – $0.23180 ⚠️ Don’t mistake a bounce for a confirmed breakout. Wait for confirmation and always manage your risk. $DNA
Mostrar más
The account equity curve looks really satisfying. I just love it when Bitcoin drops sharply $BTC. I'm still holding on to $DNA, waiting for it to make its move.
Mostrar más
$DNA DUMPS 27% | BEARISH TARGET IN SIGHT My October 19 bearish setup on #DNA continues to play out, with price now down to $0.19074, a ~27% drop from our short setup's breakdown exit point. Updated Technical Analysis: ➤ Current Price: $0.19074 ➤ Bearish Target: $0.148 ➤ Key Resistance: $0.250 ➤ Bearish Outlook: Still watching for further downside toward $0.148. The chart is doing the talking. Hope you're enjoying the analysis. Stay tuned for the next update.
Mostrar más
Gate Futures Listings | October 12–18, 2026 One-stop access to popular memes, crypto assets, stocks, and ETFs. 🔹 New: 14 futures trading pairs. As of now, Gate supports trading 482+ stock futures. 🔹 Last week's highlights: $DNA, $BATON, $CLAUDIA, $SBUX, and other futures tokens. 🔹 Long and short positions support up to 20x leverage, helping you respond flexibly to market conditions. 🔹 Join popular futures events to earn more rewards. Stock Futures Bonus Season: Share a 500,000 USDT prize pool, with up to 1,000 USDT per person. ChangXin Memory and Unitree Robotics futures trading competition: register to receive 5 USDT, with up to 240 USDT per person.
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.